跳至主要内容
临床试验/NCT04404517
NCT04404517Unknown3 期

Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks

Hospital Universitario La Paz1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2019年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
20
试验地点
1
主要终点
Adalimumab trough level

研究概览

简要总结

RCT to evaluate possible pharmacokinetic differences between the two current regimes of intensified adalimumab administration.

详细描述

IBD patients in need of intensified adalimumab treatment will be randomized to receive 40mg sc weekly or 80mg sc every two weeks, and after 6 weeks of treatment each of the groups will be allocated to the other dosing regime. Adalimumab blood levels and other features such as specific drug antibodies and disease activity parameters will be compared between both groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients > 18y
  • Intensified adalimumab regime at least 4 weeks prior to enrollment.
  • Immunosuppressants are allowed if a stable dose for > 12w is maintained.
  • Corticosteroids are allowed if they were initiated prior to enrollment and a stable dose is maintained.

排除标准

  • Patients unable to understand study protocol, study procedures or not capacitated to give informed consent.
  • Pregnant or lactating women.

研究组 & 干预措施

40mg1w

Active Comparator

Adalimumab at an administration of 40 mg weekly for 6 weeks, followed by Adalimumab at an administration of 80 mg every two weeks

干预措施: Adalimumab (Drug)

80mg2w

Active Comparator

Adalimumab at an administration of 80 mg every two weeks

干预措施: Adalimumab (Drug)

结局指标

主要结局

Adalimumab trough level

时间窗: 12 weeks

Drug levels will be measured during 12 weeks of treatment

次要结局

  • Clinical response for Ulcerative Colitis(12 weeks)
  • Clinical response for Ulcerative colitis(12 weeks)
  • Clinical response for Crohn´s Disease(12 weeks)
  • Fecal calprotectin(12 weeks)
  • Blood acute phase reactants(12 weeks)
  • Antibodies to Adalimumab (ADA)(12 weeks)
  • Treatment Satisfaction(12 weeks)
  • QOL(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

María Dolores Martín Arranz, PhD

Director

Hospital Universitario La Paz

研究点 (1)

Loading locations...

相似试验